Apex Principal Investigators Author Article With Rovi

Apex Principal Investigators, Drs. Howard Hassman and David Walling at Hassman Research Institute (HRI) and Collaborative Neuroscience Research (CNS), respectively, authored in collaboration with Rovi an article about a crucial clinical trial (NCT03527186) assessing the steady-state comparative bioavailability of risperidone in situ microimplants (ISM) and oral risperidone in 104 patients with schizophrenia. The study implemented both an inpatient and outpatient research design with repeat oral administration of once-daily 4 mg risperidone for 7 days followed by 4 monthly intramuscular doses of risperidone ISM. The results of the investigation show that the rapid release of risperidone ISM allowed the achievement of the desired levels similar to those observed at the steady-state after oral risperidone treatment, which means that directly switching after 24 hours from the last oral risperidone dose to risperidone ISM can be accomplished in schizophrenia patients without time lag. Check out the article here: https://doi.org/10.2147/DDDT.S332026